03-03-2025
Janux Therapeutics price target lowered to $41 from $62 at Scotiabank
Scotiabank lowered the firm's price target on Janux Therapeutics (JANX) to $41 from $62 and keeps a Sector Perform rating on the shares. While the dose-escalation results for the company's ongoing Phase 1 trial of JANX007 look promising, the firm does not believe all benchmarks required for establishing a competitive edge and potential pharma acquisition have been achieved, the analyst tells investors. The firm is lowering its price target to reflect a more muted outlook on JANX007 potential.
See what stocks are receiving Strong Buy ratings from top-rated analysts.
Filter, analyze, and streamline your search for investment opportunities with TipRanks' Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders' Hot Stocks on TipRanks >>
Read More on JANX:
Analyst Recommends 'Buy' for Janux Therapeutics Inc. Amid Share Price Decline and Promising Clinical Outlook
Promising Potential of Janux Therapeutics' Lead Asset and Strategic Plans Justify Buy Rating
Janux Therapeutics price target raised to $76 from $75 at Wedbush
Janux Therapeutics reports Q4 EPS (36c), consensus (45c)
Janux Therapeutics names Zachariah McIver, D.O., Ph.D. as Chief Medical Officer
